Christensen Carol H, Chang Joanne T, Rostron Brian L, Hammad Hoda T, van Bemmel Dana M, Del Valle-Pinero Arseima Y, Wang Baoguang, Mishina Elena V, Faulcon Lisa M, DePina Ana, Brown-Baker La'Nissa, Kimmel Heather L, Lambert Elizabeth, Blount Benjamin C, Vesper Huber W, Wang Lanqing, Goniewicz Maciej L, Hyland Andrew, Travers Mark J, Hatsukami Dorothy K, Niaura Raymond, Cummings K Michael, Taylor Kristie A, Edwards Kathryn C, Borek Nicolette, Ambrose Bridget K, Chang Cindy M
Office of Science, Center for Tobacco Products, FDA, Silver Spring, Maryland.
National Institute of Drug Abuse, Bethesda, Maryland.
Cancer Epidemiol Biomarkers Prev. 2021 Oct;30(10):1947-1955. doi: 10.1158/1055-9965.EPI-21-0140. Epub 2021 Jul 21.
Former smokers who currently use e-cigarettes have lower concentrations of biomarkers of tobacco toxicant exposure than current smokers. It is unclear whether tobacco toxicant exposure reductions may lead to health risk reductions.
We compared inflammatory biomarkers (high-sensitivity C-reactive protein, IL6, fibrinogen, soluble intercellular adhesion molecule-1) and an oxidative stress marker (F2-isoprostane) among 3,712 adult participants in Wave 1 (2013-2014) of the Population Assessment of Tobacco and Health Study by tobacco user groups: dual users of cigarettes and e-cigarettes; former smokers who currently use e-cigarettes-only; current cigarette-only smokers; former smokers who do not currently use any tobacco; and never tobacco users. We calculated geometric means (GM) and estimated adjusted GM ratios (GMR).
Dual users experienced greater concentration of F2-isoprostane than current cigarette-only smokers [GMR 1.09 (95% confidence interval, CI, 1.03-1.15)]. Biomarkers were similar between former smokers who currently use e-cigarettes and both former smokers who do not use any tobacco and never tobacco users, but among these groups most biomarkers were lower than those of current cigarette-only smokers. The concentration of F2-isoprostane decreased by time since smoking cessation among both exclusive e-cigarette users ( = 0.03) and former smokers who do not currently use any tobacco ( = 0.0001).
Dual users have greater concentration of F2-isoprostane than smokers. Exclusive e-cigarette users have biomarker concentrations that are similar to those of former smokers who do not currently use tobacco, and lower than those of exclusive cigarette smokers.
This study contributes to an understanding of the health effects of e-cigarettes.
目前使用电子烟的 former smokers 体内烟草毒物暴露生物标志物的浓度低于 current smokers。尚不清楚烟草毒物暴露的减少是否会降低健康风险。
我们在烟草与健康人口评估研究第 1 波（2013 - 2014 年）的 3712 名成年参与者中，按烟草使用群体比较了炎症生物标志物（高敏 C 反应蛋白、IL6、纤维蛋白原、可溶性细胞间粘附分子 - 1）和氧化应激标志物（F2 - 异前列腺素）：香烟和电子烟的双重使用者；目前仅使用电子烟的 former smokers；目前仅吸香烟的吸烟者；目前不使用任何烟草的 former smokers；以及从不使用烟草者。我们计算了几何均数（GM）并估计了调整后的 GM 比值（GMR）。
双重使用者的 F2 - 异前列腺素浓度高于目前仅吸香烟的吸烟者 [GMR 1.09（95%置信区间，CI，1.03 - 1.15）]。目前使用电子烟的 former smokers 与目前不使用任何烟草的 former smokers 和从不使用烟草者之间的生物标志物相似，但在这些群体中，大多数生物标志物低于目前仅吸香烟的吸烟者。在仅使用电子烟的使用者（ = 0.03）和目前不使用任何烟草的 former smokers（ = 0.0001）中，F2 - 异前列腺素的浓度均随戒烟时间而降低。
双重使用者的 F2 - 异前列腺素浓度高于吸烟者。仅使用电子烟的使用者的生物标志物浓度与目前不使用烟草的 former smokers 相似，且低于仅吸香烟者。
本研究有助于了解电子烟对健康的影响。
